A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...
There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...
The mRNA vaccine works by targeting genetic mutations found in pancreatic cancer, alerting the immune system to recognize and ...
A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...
A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...
Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.
The trial would combine standard surgery and chemotherapy treatments — which are the standard of care for pancreatic cancer — with a customized mRNA vaccine. Each vaccine would be designed ...
A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...